Premium
The potential therapeutic and prognostic impacts of the c‐MET/HGF signaling pathway in colorectal cancer
Author(s) -
Parizadeh Seyed Mostafa,
JafarzadehEsfehani Reza,
FazilatPanah Danial,
Hassanian Seyed Mahdi,
Shahidsales Soodabeh,
Khazaei Majid,
Parizadeh Seyed Mohammad Reza,
GhayourMobarhan Majid,
Ferns Gordon A.,
Avan Amir
Publication year - 2019
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1002/iub.2063
Subject(s) - hepatocyte growth factor , cancer research , signal transduction , c met , colorectal cancer , receptor tyrosine kinase , metastasis , angiogenesis , epithelial–mesenchymal transition , cancer , carcinogenesis , medicine , tyrosine kinase , cell growth , biology , receptor , microbiology and biotechnology , genetics
Colorectal cancer (CRC) is the third most common cancer and a common cause of cancer‐related mortality globally. In spite of the improvements in the early diagnosis of CRC, approximately one‐third of patients develop metastasis and then have a very poor survival rate. The mesenchymal–epithelial transition factor (c‐MET) is a tyrosine kinase cell surface receptor activated by hepatocyte growth factor (HGF). Activation of c‐MET/HGF signaling pathway regulates a variety of biological processes including cell motility, cell proliferation, angiogenesis, the epithelial‐to‐mesenchymal transition, and the development and progression of cancer cells. Recent studies have suggested that the c‐MET/HGF signaling pathway is involved in the carcinogenesis of CRC. In this review, we summarize the main findings of recent studies investigating the role of c‐MET/HGF signaling pathway in CRC and the potential of the c‐MET/HGF signaling pathways in the diagnosis and treatment of CRC. © 2019 IUBMB Life, 2019